Vaccines

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.

VUMC scientists ‘sprint’ to find anti-Zika antibodies

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

2018 a year of growth, achievement for VUMC

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2018.

Study tests new vaccine for precancerous cervical cells

Vanderbilt University Medical Center is participating in an international study to determine the effectiveness of a new therapeutic vaccine for treating women with precancerous changes on the cervix.

Discovery could lead to neutralizing West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Symposium to focus on prospects for a universal flu vaccine

Internationally known vaccine experts including Vanderbilt University’s James Crowe Jr., MD, will speak next month at a symposium in Nashville on prospects for a universal flu vaccine.

Team isolates antibodies that neutralize GI bug norovirus

Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.

1 8 9 10 11 12 14